The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3053-3060

  Dawson, Heather ^a   Andre, Sabine ^b   Karamitopoulou, Eva ^a   Zlobec, Inti ^a   Gabius, Hans Joachim ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Glycosylation; Invasion; Lectin; Prognosis

Indexed keywords

BETA CATENIN; ECALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 7; K RAS PROTEIN; PROTEIN BCL 2; SYNEXIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHEMOREACTIVITY; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR INVASION;

APOPTOSIS; GLYCOSYLATION; INVASION; LECTIN; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; CYTOPLASM; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; STAINING AND LABELING;

EID: 84883302212     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Caselitz J: Lectins and blood group substances as tumor markers. Curr Top Pathol 77: 245-278, 1987.
2. Dabelsteen E: Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 179: 358-369, 1996.
3. Roth J: Lectins for histochemical demonstration of glycans. Histochem Cell Biol 136: 117-130, 2011.
4. Patsos G and Corfield A: O-Glycosylation: structural diversity and functions. In: The Sugar Code. Fundamentals of Glycosciences. Gabius HJ (ed.). Wiley-VCH, Weinheim, pp. 111-137, 2009.
5. Zuber C and Roth J: N-Glycosylation. In: The Sugar Code. Fundamentals of Glycosciences. Gabius HJ (ed.). Wiley-VCH, Weinheim, pp. 87-110, 2009.
6. Sharon N and Lis H: Glycoproteins: structure and function. In: Glycosciences: Status and Perspectives. Gabius HJ and Gabius S (eds.). Chapman & Hall, Weinheim, pp. 133-162, 1997.
7. Gabius HJ, van de Wouver M, Andre S and Villalobo A: Downregulation of the epidermal growth factor receptor by altering Nglycosylation: Emerging role of β1,4-galactosyltransferases. Anticancer Res 32: 1565-1572, 2012.
8. Gabius HJ, Engelhardt R and Cramer F: Endogenous tumor lectins: Overview and perspectives. Anticancer Res 6: 573-578, 1986.
9. Gabius HJ, Andre S, Jimenez-Barbero J, Romero A and Solis D: From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem Sci 36: 298-313, 2011.
10. Andre S, Sanchez-Ruderisch H, Nakagawa H, Buchholz M, Kopitz J, Forberich P, Kemmner W, Bock C, Deguchi K, Detjen KM, Wiedenmann B, von Knebel Doeberitz M, Gress TM, Nishimura SI, Rosewicz S and Gabius HJ: Tumor suppressor p16INK4a: modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. FEBS J 274: 3233-3256, 2007.
11. Sanchez-Ruderisch H, Fischer C, Detjen KM, Welzel M, Wimmel A, Manning JC, Andre S and Gabius HJ: Tumor suppressor p16INK4a: Down-regulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J 277: 3552-3563, 2010.
12. Amano M, Eriksson H, Manning JC, Detjen KM, Andre S, Nishimura SI, Lehtio J and Gabius HJ: Tumor suppressor p16INK4a: Anoikis-favouring decrease in N/O-glycan/cell surface sialylation by down-regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model. FEBS J 279: 4062-4080, 2012.
13. Kaltner H and Gabius HJ: A toolbox of lectins for translating the sugar code: The galectin network in phylogenesis and tumors. Histol Histopathol 27: 397-416, 2012.
14. Smetana K Jr, Andre S, Kaltner H, Kopitz J and Gabius HJ: Context-dependent multifunctionality of galectin-1: A challenge for defining the lectin as therapeutic target. Exp Opin Ther Targ 17: 379-392, 2013.
15. Gabius HJ, Grote T, Gabius S, Brinck U and Tietze LF: Neoglycoprotein binding to colorectal tumour cells: Comparison between primary and secondary lesions. Virchows Arch A Pathol Anat Histopathol 419: 217-222, 1991.
16. Schoeppner HL, Raz A, Ho SB and Bresalier RS: Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75: 2818-2826, 1995.
17. Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Nakajima A, Hida JI, Miyake M, Shindo K and Yasutomi M: Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15: 143-148, 1999.
18. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, Zick Y, Salmon I, Danguy A, Kiss R and Gabius HJ: Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50: 392-401, 2002.
19. Nagy N, Legendre H, Engels O, Andre S, Kaltner H, Wasano K, Zick Y, Pector JC, Decaestecker C, Gabius HJ, Salmon I and Kiss R: Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 97: 1849-1858, 2003.
20. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H, Baba H and Maehara Y: Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 25: 3117-3121, 2005.
21. Saal I, Nagy N, Lensch M, Lohr M, Manning JC, Decaestecker C, Andre S, Kiss R, Salmon I and Gabius HJ: Human galectin- 2: Expression profiling by RT-PCR/immunohistochemistry and its introduction as a histochemical tool for ligand localization. Histol Histopathol 20: 1191-1208, 2005.
22. Gebert J, Kloor M, Lee J, Lohr M, Andre S, Wagner R, Kopitz J and Gabius HJ: Colonic carcinogenesis along different genetic routes: Glycophenotyping of tumor cases separated by microsatellite instability/stability. Histochem Cell Biol 138: 339-350, 2012.
23. Barrow H, Rhodes JM and Yu LG: The role of galectins in colorectal cancer progression. Int J Cancer 129: 1-8, 2011.
24. Ohannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HJ and Lotan R: Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55: 2191-2199, 1995.
25. Krzeminski M, Singh T, Andre S, Lensch M, Wu AM, Bonvin AMJJ and Gabius HJ: Human galectin-3 (Mac-2 antigen): Defining molecular switches of affinity to natural glycoproteins, structural and dynamic aspects of glycan binding by flexible ligand docking and putative regulatory sequences in the proximal promoter region. Biochim Biophys Acta 1810: 150-161, 2011.
26. Nangia-Makker P, Nakahara S, Hogan V and Raz A: Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 39: 79-84, 2007.
27. Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E and Gabius HJ: Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127: 375-386, 2001.
28. Cludts S, Decaestecker C, Mahillon V, Chevalier D, Kaltner H, Andre S, Remmelink M, Leroy X, Gabius HJ and Saussez S: Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin 1, -3 and -7. Anticancer Res 29: 4933-4940, 2009.
29. Cada Z, Chovanec M, Smetana K Jr, Betka J, Lacina L, Plzak J, Kodet R, Stork J, Lensch M, Kaltner H, Andre S and Gabius HJ: Galectin-7: Will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas? Histol Histopathol 24: 41-48, 2009.
30. Fik Z, Valach J, Chovanec M, Mazanek J, Kodet R, Kodet O, Tachezy R, Foltynova E, Andre S, Kaltner H, Gabius HJ and Smetana K Jr: Loss of adhesion/growth-regulatory galectin-9 from squamous cell epithelium in head and neck carcinomas. J Oral Pathol Med 42: 166-173, 2013.
31. Gabius HJ, Walzel H, Joshi SS, Kruip J, Kojima S, Gerke V, Kratzin H and Gabius S: The immunomodulatory β-galactosidespecific lectin from mistletoe: Partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells. Anticancer Res 12: 669-675, 1992.
32. Habermann FA, Andre S, Kaltner H, Kubler D, Sinowatz F and Gabius HJ: Galectins as tools for glycan mapping in histology: Comparison of their binding profiles to the bovine zona pellucida by confocal laser scanning microscopy. Histochem Cell Biol 135: 539-552, 2011.
33. Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, Cantz M and Gabius HJ: Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 276: 35917-35923, 2001.
34. Saussez S, de Leval L, Decaestecker C, Sirtaine N, Cludts S, Duray A, Chevalier D, Andre S, Gabius HJ, Remmelink M and Leroy X: Galectin fingerprinting in Warthin's tumors: Lectinbased approach to trace its origin? Histol Histopathol 25: 541-550, 2010.
35. Remmelink M, de Leval L, Decaestecker C, Duray A, Crompot E, Sirtaine N, Andre S, Kaltner H, Leroy X, Gabius HJ and Saussez S: Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumours: Divergent profiles with diagnostic potential. Histopathology 58: 543-556, 2011.
36. Schlotzer-Schrehardt U, Andre S, Janko C, Kaltner H, Kopitz J, Gabius HJ and Herrmann M: Adhesion/growth-regulatory galectins in the human eye: Localization profiles and tissue reactivities as a standard to detect disease-associated alterations. Graefes Arch Clin Exp Ophthalmol 250: 1169-1180, 2012.
37. Plzak J, Betka J, Smetana K Jr., Chovanec M, Kaltner H, Andre S, Kodet R and Gabius HJ: Galectin-3: An emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer 40: 2324-2330, 2004.
38. Yang RY, Hsu DK and Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93: 6737-6742, 1996.
39. Akahani S, Nangia-Makker P, Inohara H, Kim HR and Raz A: Galectin-3: A novel molecule with a functional BH1 (NWGR) domain of BCL-2 family. Cancer Res 57: 5272-5276, 1997.
40. Yu F, Finley RL Jr, Raz A and Kim HR: Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277: 15819-15827, 2002.
41. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of β-catenin. Cancer Res 64: 6363-6367, 2004.
42. Levy R, Biran A, Poirier F, Raz A and Kloog Y: Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA. PLoS One 6: e27490, 2011.
43. Liu W, Hsu DK, Chen HY, Yang RY, Carraway KL 3rd, Isseroff RR and Liu FT: Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration. J Invest Dermatol 132: 2828-2837, 2012.
44. Zlobec I, Bihl MP, Schwarb H, Terracciano L and Lugli A: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 127: 367-380, 2010.
45. Benedix F, Meyer F, Kube R, Kropf S, Kuester D, Lippert H, Roessner A and Kruger S: Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract 208: 592-597, 2012.
46. Patsos G, Andre S, Roeckel N, Gromes R, Gebert J, Kopitz J and Gabius HJ: Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): A genedependent effect on the cell surface glycan profile. Glycobiology 19: 726-734, 2009.
47. Poeta ML, Massi E, Parrella P, Pellegrini P, De Robertis M, Copetti M, Rabitti C, Perrone G, Muda AO, Molinari F, Zanellato E, Crippa S, Caputo D, Caricato M, Frattini M, Coppola R and Fazio VM: Aberrant promoter methylation of β1,4 galactosyltransferase- I as potential cancer-specific biomarker of colorectal tumors. Genes Chromosomes Cancer 51: 1133-1143, 2012.